DK2651922T3 - Indoler som respiratorisk syncytialvirus-antivirale midler - Google Patents
Indoler som respiratorisk syncytialvirus-antivirale midler Download PDFInfo
- Publication number
- DK2651922T3 DK2651922T3 DK11794793.7T DK11794793T DK2651922T3 DK 2651922 T3 DK2651922 T3 DK 2651922T3 DK 11794793 T DK11794793 T DK 11794793T DK 2651922 T3 DK2651922 T3 DK 2651922T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound according
- group
- compound
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (24)
1. Forbindelse med formlen (I), et N-oxid, et additionssalt, en kvaternær amin, et metalkompleks eller en stereokemisk isomer form deraf;
hvor hvert X uafhængigt er C eller N; Ri er valgt fra gruppen bestående af H, halogen, (Ci-Ce) alkoxy, CF3 og OCF3; R2 er valgt fra gruppen bestående af H, halogen, (Ci-C6) alkyl, (C3-C7) cycloalkyl, (Ci-C6) alkoxy og CO(R7); R3 er - (CRgRg) n-Rio; R4 er valgt fra gruppen bestående af H, (C1-C10) alkyl, (C3-C7) cycloalkyl, (C2-Cio) alkenyl, S02-R8, CH2CF3, S02CH3 eller en 4 til 6-leddet mættet ring, som indeholder et oxygenatom; R5 er til stede, hvor X er C, og er valgt fra gruppen bestående af H, (Ci-C6) alkyl, (C3-C7) cycloalkyl, (Ci-C6) alkoxy, CO(R7), CF3 og halogen; R5 er fraværende, hvor X er N; R7 er valgt fra gruppen bestående af OH, 0 ( (Οχ-Οε) alkyl) , NH2, NHS02N( (Ci-C6) alkyl) 2, NHS02NHCH3, NHS02 ( (Ci-C6) alkyl) , NHS02 ( (C3-C7) cycloalkyl) og N ( (Ci-C6) alkyl) 2, NR8R9, NR9Ri0; n er et heltal fra 2 til 6; Rg og R9 hver er uafhængigt valgt blandt H, (C1-C10) alkyl, (C3-C7) cycloalkyl, eller Rg og R9 taget sammen udgør en 4 til 6-leddet alifatisk ring, som eventuelt indeholder et eller flere heteroatomer valgt fra gruppen N, S, 0; Rio er valgt fra gruppen bestående af H, (Ci-C6) alkyl, OH, CN, F, CF2H, CF3, C(=N0H)NH2, CONRgRg, COORg, C0NR8S02R9, CON (Rg) S02N (RgRg) , NRgRg, NRgCOORg, OCORg, NR8S02R9, S02NR8R9, S02Rg eller en 4 til 6-leddet mættet ring, som indeholder et oxygenatom.
2. Forbindelse ifølge krav 1, hvor R4 er valgt fra gruppen bestående af H, (C1-C10) alkyl, (C3- C7) cycloalkyl, (C2-Cio) alkenyl, SO2-R8 eller en 4 til 6-leddet mættet ring, som indeholder et oxygenatom.
3. Forbindelse ifølge krav 1 eller 2, hvor Ri er valgt fra gruppen bestående af H og halogen.
4. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor Ri i para-positionen i forhold til N-R3 er valgt fra gruppen bestående af H og halogen, og alle andre Ri er H.
5. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor Ri er valgt fra gruppen bestående af brom og chlor.
6. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R2 er valgt fra gruppen bestående af H, halogen og CO (R7) .
7. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R2 er valgt fra gruppen bestående af Η, I og CONH2.
8. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R3 omfatter en - (CR8R9) n_kæde, hvor R8 og R9 er H, og n er 2-4.
9. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor Ri0 er valgt fra gruppen bestående af F, CF3, OH, S02R8 og CN, hvor R8 fortrinsvis er methyl.
10. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R4 er (C3-C7) cycloalkyl, fortrinsvis cyclopropyl eller CH2CF3.
11. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R4 er isopropyl.
12. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R4 er oxetan-3-yl.
13. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor X i para-positionen i forhold til N-R4 er C, og R5 på det X er F.
14. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor ét X er N, og de andre X'er er C, idet N fortrinsvis er i para-position i forhold til N-R4.
15. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor højst ét R5 er valgt fra gruppen bestående af (C4 — Οε) alkyl, (Cp-Ce) alkoxy og halogen, og de andre R5 er H.
16. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor alle R5 er H.
17. Forbindelse ifølge krav 1, hvor forbindelsen er
eller et N-oxid, et additionssalt, en kvaternær amin eller et metalkompleks deraf.
18. Forbindelse ifølge krav 17, hvor forbindelsen er
19. Forbindelse ifølge et hvilket som helst af kravene 1-18 til anvendelse som lægemiddel.
20. Farmaceutisk sammensætning, som omfatter en farmaceutisk acceptabel bærer og, som aktiv bestanddel, en terapeutisk effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1-18.
21. Fremgangsmåde til fremstilling af en farmaceutisk sammensætning ifølge krav 20, hvilken fremgangsmåde omfatter grundig blanding af en farmaceutisk acceptabel bærer med en terapeutisk effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1-18.
22. Forbindelse ifølge et hvilket som helst af kravene 1-18 til anvendelse som lægemiddel til hæmning af RSV-replikation.
23. Fremgangsmåde til fremstilling af en forbindelse ifølge et hvilket som helst af kravene 1-16, hvilken fremgangsmåde omfatter kobling af en forbindelse valgt fra gruppen bestående af Il-a, ΙΙ-b og II-c med en forbindelse III, hvilken kobling fører til derivater med formlen (I), hvor alle substituenterne R og X har en betydning, som er i overensstemmelse med krav 1.
24. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1-18 til fremstilling af et lægemiddel til hæmning af RSV-replikation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10195468 | 2010-12-16 | ||
| PCT/EP2011/073011 WO2012080447A1 (en) | 2010-12-16 | 2011-12-16 | Indoles as respiratory syncytial virus antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2651922T3 true DK2651922T3 (da) | 2016-05-30 |
Family
ID=43875270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11794793.7T DK2651922T3 (da) | 2010-12-16 | 2011-12-16 | Indoler som respiratorisk syncytialvirus-antivirale midler |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US8921560B2 (da) |
| EP (1) | EP2651922B1 (da) |
| JP (2) | JP5945278B2 (da) |
| KR (1) | KR101914606B1 (da) |
| CN (1) | CN103347875B (da) |
| AR (1) | AR084335A1 (da) |
| AU (1) | AU2011343256C1 (da) |
| BR (1) | BR112013011949B1 (da) |
| CA (1) | CA2822000C (da) |
| CL (1) | CL2013001715A1 (da) |
| CY (1) | CY1117763T1 (da) |
| DK (1) | DK2651922T3 (da) |
| EA (1) | EA022339B1 (da) |
| ES (1) | ES2572258T3 (da) |
| HK (1) | HK1185613A1 (da) |
| HR (1) | HRP20160533T1 (da) |
| HU (1) | HUE028009T2 (da) |
| IL (1) | IL225641A (da) |
| ME (1) | ME02406B (da) |
| MX (1) | MX339944B (da) |
| MY (1) | MY163981A (da) |
| NZ (1) | NZ609487A (da) |
| PL (1) | PL2651922T3 (da) |
| RS (1) | RS54746B1 (da) |
| SG (1) | SG189866A1 (da) |
| SI (1) | SI2651922T1 (da) |
| SM (1) | SMT201600142B (da) |
| TW (1) | TWI515187B (da) |
| UA (1) | UA109792C2 (da) |
| WO (1) | WO2012080447A1 (da) |
| ZA (1) | ZA201304423B (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| JP2015519387A (ja) * | 2012-06-15 | 2015-07-09 | ヤンセン・アールアンドデイ・アイルランド | Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体 |
| AR091455A1 (es) | 2012-06-15 | 2015-02-04 | Janssen R & D Ireland | Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio |
| KR20150032329A (ko) * | 2012-07-10 | 2015-03-25 | 에프. 호프만-라 로슈 아게 | 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 인다졸 |
| SI2909195T1 (sl) | 2012-10-16 | 2017-10-30 | Janssen Sciences Ireland Uc | RSV protivirusni sestavki |
| BR112016003348B1 (pt) | 2013-08-21 | 2023-03-07 | Alios Biopharma, Inc | Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| CN106999509A (zh) * | 2014-08-05 | 2017-08-01 | 艾丽奥斯生物制药有限公司 | 用于治疗副粘病毒的联合治疗 |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| WO2017015449A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| IL300788A (en) | 2015-11-20 | 2023-04-01 | Forma Therapeutics Inc | Furinones as ubiquitin-specific protease 1 inhibitors |
| WO2017123884A1 (en) | 2016-01-15 | 2017-07-20 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EP3411028B1 (en) | 2016-02-03 | 2021-05-05 | Janssen Sciences Ireland Unlimited Company | Combination product for treating or ameliorating respiratory syncytial virus infection |
| US20200288710A1 (en) | 2016-03-15 | 2020-09-17 | Bayer Cropscience Aktiengesellschaft | Substituted sulphonamides for controlling animal pests |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
| EP3710009A4 (en) | 2017-11-13 | 2021-08-25 | Enanta Pharmaceuticals, Inc. | METHOD FOR THE RESOLUTION OF BENZODIAZEPIN-2-ONE AND BENZOAZEPIN-2-ONE DERIVATIVES |
| TW201936193A (zh) * | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療ｒｓｖ |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2021066922A1 (en) | 2019-10-04 | 2021-04-08 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| US20240109894A1 (en) * | 2019-10-30 | 2024-04-04 | Janssen Sciences Ireland Unlimited Company | Synthesis of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2-yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one |
| WO2021089673A1 (de) | 2019-11-07 | 2021-05-14 | Bayer Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| JP2023528969A (ja) | 2020-06-11 | 2023-07-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ３－（｛５－クロロ－１－［３－（メチルスルホニル）プロピル］－１Ｈ－インドール－２ イル｝メチル）－１－（２，２，２－トリフルオロエチル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オンのヘミ（Ｌ）－酒石酸塩形態及びそれを含む医薬組成物 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| JP2024507561A (ja) | 2021-02-26 | 2024-02-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス複素環式化合物 |
| WO2022184606A1 (en) | 2021-03-01 | 2022-09-09 | Janssen Sciences Ireland Unlimited Company | Synthesis of rilematovir |
| CN114014856B (zh) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ333696A (en) | 1996-07-08 | 2000-06-23 | Du Pont Pharm Co | Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor |
| AU1099000A (en) | 1998-10-05 | 2000-04-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| PL349192A1 (en) | 1998-12-18 | 2002-07-01 | Axys Pharmaceuticals | Protease inhibitors |
| PT1196408E (pt) | 1999-06-28 | 2005-01-31 | Janssen Pharmaceutica Nv | Inibidores da replicacao do virus sincicial respiratorio |
| WO2001000612A2 (en) | 1999-06-28 | 2001-01-04 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| US6534535B1 (en) * | 1999-08-12 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| WO2001057019A1 (en) * | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| EP1255750A1 (en) * | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| US6489338B2 (en) * | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
| US6506738B1 (en) | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
| JP2005511714A (ja) | 2001-12-10 | 2005-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | Ｒｓｖ融合インヒビターのジ塩酸塩・モノ水和物 |
| US6919331B2 (en) * | 2001-12-10 | 2005-07-19 | Bristol-Myers Squibb Company | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents |
| GB2384778A (en) | 2001-12-21 | 2003-08-06 | Sense Proteomic Ltd | Probe for mass spectrometry |
| WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| US7343930B2 (en) | 2004-12-03 | 2008-03-18 | Masco Corporation Of Indiana | Sprayer with non-faucet control |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| CA2687821C (en) | 2007-05-22 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Benzimidazolone chymase inhibitors |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| TWI530495B (zh) * | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| TWI515187B (zh) * | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI541241B (zh) * | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| DK3603704T3 (da) | 2010-12-17 | 2023-07-24 | Sanofi Aventis Deutschland | Indgivelse af medikament |
| JP2015519387A (ja) | 2012-06-15 | 2015-07-09 | ヤンセン・アールアンドデイ・アイルランド | Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体 |
| CN104470916A (zh) | 2012-06-15 | 2015-03-25 | 爱尔兰詹森研发公司 | 新颖的作为呼吸道合胞病毒抗病毒剂的被苯并咪唑取代的1,3-二氢-2h-苯并咪唑-2-酮衍生物 |
| AR091455A1 (es) | 2012-06-15 | 2015-02-04 | Janssen R & D Ireland | Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio |
| WO2013186332A1 (en) | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 4 - substituted 1, 3 - dihydro - 2h - benzimidazol - 2 - one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents |
| SI2909195T1 (sl) | 2012-10-16 | 2017-10-30 | Janssen Sciences Ireland Uc | RSV protivirusni sestavki |
-
2011
- 2011-12-15 TW TW100146391A patent/TWI515187B/zh active
- 2011-12-16 KR KR1020137016980A patent/KR101914606B1/ko active IP Right Grant
- 2011-12-16 EA EA201390883A patent/EA022339B1/ru unknown
- 2011-12-16 CA CA2822000A patent/CA2822000C/en active Active
- 2011-12-16 BR BR112013011949-7A patent/BR112013011949B1/pt active IP Right Grant
- 2011-12-16 ME MEP-2016-97A patent/ME02406B/me unknown
- 2011-12-16 NZ NZ609487A patent/NZ609487A/en unknown
- 2011-12-16 DK DK11794793.7T patent/DK2651922T3/da active
- 2011-12-16 CN CN201180060358.8A patent/CN103347875B/zh active Active
- 2011-12-16 RS RS20160332A patent/RS54746B1/sr unknown
- 2011-12-16 MX MX2013006887A patent/MX339944B/es active IP Right Grant
- 2011-12-16 SG SG2013026729A patent/SG189866A1/en unknown
- 2011-12-16 ES ES11794793T patent/ES2572258T3/es active Active
- 2011-12-16 WO PCT/EP2011/073011 patent/WO2012080447A1/en active Application Filing
- 2011-12-16 SI SI201130824A patent/SI2651922T1/sl unknown
- 2011-12-16 UA UAA201304193A patent/UA109792C2/ru unknown
- 2011-12-16 EP EP11794793.7A patent/EP2651922B1/en active Active
- 2011-12-16 HU HUE11794793A patent/HUE028009T2/en unknown
- 2011-12-16 PL PL11794793.7T patent/PL2651922T3/pl unknown
- 2011-12-16 US US13/993,200 patent/US8921560B2/en active Active
- 2011-12-16 MY MYPI2013001279A patent/MY163981A/en unknown
- 2011-12-16 AU AU2011343256A patent/AU2011343256C1/en active Active
- 2011-12-16 AR ARP110104740A patent/AR084335A1/es active IP Right Grant
- 2011-12-16 JP JP2013543801A patent/JP5945278B2/ja active Active
-
2013
- 2013-04-09 IL IL225641A patent/IL225641A/en active IP Right Grant
- 2013-06-13 CL CL2013001715A patent/CL2013001715A1/es unknown
- 2013-06-14 ZA ZA2013/04423A patent/ZA201304423B/en unknown
- 2013-11-21 HK HK13113019.5A patent/HK1185613A1/zh unknown
-
2014
- 2014-11-18 US US14/546,289 patent/US9321768B2/en active Active
-
2016
- 2016-03-11 JP JP2016048038A patent/JP2016145236A/ja active Pending
- 2016-04-22 US US15/136,769 patent/US9944638B2/en active Active
- 2016-05-19 HR HRP20160533TT patent/HRP20160533T1/hr unknown
- 2016-05-20 SM SM201600142T patent/SMT201600142B/it unknown
- 2016-05-24 CY CY20161100449T patent/CY1117763T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2651922T3 (da) | Indoler som respiratorisk syncytialvirus-antivirale midler | |
| EP2651936A1 (en) | Azaindoles as respiratory syncytial virus antiviral agents | |
| WO2013186334A1 (en) | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents | |
| AU2014209853B2 (en) | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents | |
| WO2012080449A1 (en) | Azabenzimidazoles as respiratory syncytial virus antiviral agents | |
| AU2013276518A1 (en) | 4 - substituted 1, 3 - dihydro - 2H - benzimidazol - 2 - one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents | |
| EP2864323B1 (en) | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | |
| AU2013276521A1 (en) | 1,3 -dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents |